Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › gefitinib

gefitinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of gefitinib

34 trials tracked of gefitinib: 11 in phase 3 or 4 and 1 with published results. The most-cited published study has 123 citations.

34Trials tracked
11Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 8 Phase 2 22 Other / NA 1
  1. Phase 3 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Completed · 123 cited
  2. Phase 4 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed
  3. Phase 4 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Completed
  4. Phase 4 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed
  5. Phase 3 Iressa Follow-up Trial Completed
  6. Phase 3 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed
Show 28 more trials
  1. Phase 3 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed
  2. Phase 3 A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer Completed
  3. Phase 3 First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia Completed
  4. Phase 3 Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients Completed
  5. Phase 3 A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone Completed
  6. Phase 2 Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
  7. Phase 2 First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Completed
  8. Phase 2 Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene Completed
  9. Phase 2 Phase II Iressa & Carbo/Gem in NSCLC Completed
  10. Phase 2 Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer Completed
  11. Phase 2 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Completed
  12. Phase 2 Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Completed
  13. Phase 2 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) Completed
  14. Phase 2 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed
  15. Phase 2 Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer Completed
  16. Phase 2 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
  17. Phase 2 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed
  18. Phase 2 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Completed
  19. Phase 2 Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers Completed
  20. Phase 2 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed
  21. Phase 2 Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone Completed
  22. Phase 2 A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Completed
  23. Phase 2 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed
  24. Phase 2 Iressa Study in Patients With Salivary Gland Cancer Completed
  25. Phase 2 A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment Completed
  26. Phase 2 Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Completed
  27. Phase 2 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) Completed
  28. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer
Allergy & Immunology Sys. Review
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer mRNA Vaccines Show Promise for Lung Cancer Treatment
This systematic review examines the current status and prospects of mRNA vaccines for lung cancer. The authors synthesize evidence that mRNA…
New research explores how mRNA technology can reshape the tumor environment and trigger immune responses to fight lung cancer.
Frontiers Aug 26, 2026
Mefatinib improves median IRC-assessed progression-free survival to 13.7 months versus 9.7 months for gefitinib
Oncology RCT
Mefatinib improves median IRC-assessed progression-free survival to 13.7 months versus 9.7 months for gefitinib Trial shows mefatinib improves progression-free survival in lung cancer
This Phase III randomized trial of 336 patients with advanced nonsquamous NSCLC harboring EGFR L858R or exon 19 deletion found mefatinib (60…
A Phase III trial found that mefatinib may extend progression-free survival for patients with specific types of advanced non-small cell lung…
Aug 14, 2026
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
Oncology RCT
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases Rezivertinib shows longer brain metastasis control than gefitinib in lung cancer trial
A phase III randomized controlled trial in 159 treatment-naïve patients with EGFR-mutated NSCLC and baseline CNS metastases found rezivertin…
Rezivertinib kept brain cancer growth in lung cancer patients under control for nearly two years longer than gefitinib in a major trial.
Apr 4, 2026